Royal Bank of Canada’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-315
| Closed | – | – | 7892 |
|
|
2023
Q3 | $0 | Sell |
315
-12,295
| -98% | -$10.7K | ﹤0.01% | 7867 |
|
|
2023
Q2 | $4K | Buy |
12,610
+1,779
| +16% | +$638 | ﹤0.01% | 6765 |
|
|
2023
Q1 | $5K | Buy |
10,831
+10,631
| +5,316% | +$5.6K | ﹤0.01% | 6596 |
|
|
2022
Q4 | $0 | Sell |
200
-2,068
| -91% | -$1.31K | ﹤0.01% | 7987 |
|
|
2022
Q3 | $2K | Buy |
+2,268
| New | +$2.57K | ﹤0.01% | 7105 |
|
|
2022
Q2 | – | Sell |
-3,925
| Closed | -$8K | – | 7927 |
|
|
2022
Q1 | $8K | Buy |
+3,925
| New | +$9.33K | ﹤0.01% | 7080 |
|
|
2021
Q4 | – | Sell |
-2,170
| Closed | -$9K | – | 8030 |
|
|
2021
Q3 | $9K | Sell |
2,170
-3,353
| -61% | -$15K | ﹤0.01% | 7016 |
|
|
2021
Q2 | $29K | Sell |
5,523
-8,706
| -61% | -$41.9K | ﹤0.01% | 6374 |
|
|
2021
Q1 | $66K | Buy |
14,229
+13,729
| +2,746% | +$62.2K | ﹤0.01% | 5720 |
|
|
2020
Q4 | $2K | Sell |
500
-40,608
| -99% | -$154K | ﹤0.01% | 6892 |
|
|
2020
Q3 | $136K | Sell |
41,108
-701
| -2% | -$2.58K | ﹤0.01% | 4797 |
|
|
2020
Q2 | $141K | Sell |
41,809
-15,928
| -28% | -$75.3K | ﹤0.01% | 4649 |
|
|
2020
Q1 | $220K | Buy |
57,737
+6,437
| +13% | +$29.9K | ﹤0.01% | 4262 |
|
|
2019
Q4 | $310K | Buy |
51,300
+10,494
| +26% | +$71.8K | ﹤0.01% | 4314 |
|
|
2019
Q3 | $308K | Sell |
40,806
-3,170
| -7% | -$35.7K | ﹤0.01% | 4159 |
|
|
2019
Q2 | $596K | Buy |
43,976
+3,530
| +9% | +$40.8K | ﹤0.01% | 3733 |
|
|
2019
Q1 | $219K | Buy |
40,446
+20,262
| +100% | +$98.6K | ﹤0.01% | 4306 |
|
|
2018
Q4 | $60K | Sell |
20,184
-35,635
| -64% | -$195K | ﹤0.01% | 5000 |
|
|
2018
Q3 | $438K | Buy |
55,819
+54,467
| +4,029% | +$418K | ﹤0.01% | 3983 |
|
|
2018
Q2 | $13K | Sell |
1,352
-2,998
| -69% | -$30.7K | ﹤0.01% | 5742 |
|
|
2018
Q1 | $37K | Sell |
4,350
-1,190
| -21% | -$12.8K | ﹤0.01% | 5195 |
|
|
2017
Q4 | $70K | Buy |
5,540
+2,652
| +92% | +$30.4K | ﹤0.01% | 5020 |
|
|
2017
Q3 | $24K | Buy |
2,888
+2,780
| +2,574% | +$29.4K | ﹤0.01% | 5865 |
|
|
2017
Q2 | $2K | Buy |
108
+106
| +5,300% | +$2.11K | ﹤0.01% | 6307 |
|
|
2017
Q1 | $0 | Sell |
2
-98
| -98% | -$1.95K | ﹤0.01% | 6893 |
|
|
2016
Q4 | $2K | Buy |
+100
| New | +$1.35K | ﹤0.01% | 6498 |
|
|
2015
Q4 | – | Sell |
-100
| Closed | -$1K | – | 6884 |
|
|
2015
Q3 | $1K | Buy |
+100
| New | +$2.46K | ﹤0.01% | 6535 |
|
Royal Bank of Canada's ZYNE Position: Q4 2023 in Review
Royal Bank of Canada sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2023, closing a stake of 315 shares.
Royal Bank of Canada first reported a position in ZYNE in Q3 2015 and held it in 27 quarters. The position peaked at $596K in Q2 2019. 0 funds tracked by Wall St. Rank hold ZYNE as of Q4 2023.
- Royal Bank of Canada reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2023 after selling out during the quarter.
- Royal Bank of Canada sold 315 Zynerba Pharmaceuticals, Inc shares in Q4 2023.
- Royal Bank of Canada first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2015 and held it in 27 quarters.
- Royal Bank of Canada's Zynerba Pharmaceuticals, Inc position peaked at $596K in Q2 2019.
- 0 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2023.
Based on Royal Bank of Canada's 13F filing for Q4 2023, filed 14 Feb 2024.